TITLE

CLINIC ROUNDUP

PUB. DATE
December 2007
SOURCE
BioWorld Today;12/4/2007, Vol. 18 Issue 234, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section provides news briefs on the biotechnology industry as of December 4, 2007. Avicena Group Inc. of California reported positive Phase II data from its combination trial involving AL-08, a second-generation drug candidate for amyotrophic lateral sclerosis. Can-Fite BioPharma Ltd. of Israel submitted an investigational new drug application to start Phase I testing of CF102 for liver diseases. Ferring Pharmaceuticals of Switzerland completed the pivotal Phase III study for degarelix, its novel prostate cancer treatment.
ACCESSION #
27730184

 

Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;5/25/2010, Vol. 21 Issue 100, p7 

    This section offers news briefs on clinical trials in the biopharmaceutical industry as of May 25, 2010. The Israeli Ministry of Health has given its approval for the Phase II trial of orally administered CF101 in glaucoma by Can-Fite BioPharma Ltd. The Swedish Medical Products Agency has...

  • CLINIC ROUNDUP.  // BioWorld Today;4/17/2009, Vol. 20 Issue 73, p5 

    This section offers news briefs on clinical trials within the biotechnology industry. The Israel Ministry of Health and Rabin MC Ethics Committee have approved the Phase I/II trial of Can-Fite BioPharma for CF102 for the treatment of liver cancer. Diamyd Medical AB plans to cut costs by...

  • Dermatology.  // CenterWatch Weekly;4/6/2015, Vol. 19 Issue 13, p9 

    This article discusses the results of a phase II/III trial by pharmaceutical company Can-Fite BioPharma on the efficacy of the drug CF101 in patients with moderate-to-severe plaque psoriasis.

  • Avicena to conduct trial for Huntington's disease drug.  // PharmaWatch: CNS;Aug2007, Vol. 6 Issue 8, p10 

    The article reports that biotechnology company Avicena Group Inc. will conduct a Phase III trial for its novel drug HD-02 for the treatment of Huntington's disease. The said study will evaluate HD-02 in a range of doses from 10 to 40 grams per day to determine the optimal dose of the drug that...

  • CAN-FITE BIOPHARMA INITIATES CF102 TRIAL FOR LIVER CANCER.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p8 

    This article reports on the plan of Can-Fite BioPharma of Israel to conduct a I/II clinical trial with CF102 for the treatment of liver cancer in 2009. Can-Fite announced that it will start enrolling patients for the clinical trial. The company will investigate the safety and efficacy of CF102...

  • CLINIC ROUNDUP.  // BioWorld Today;5/6/2008, Vol. 19 Issue 88, p4 

    This section offers news briefs on the pharmaceutical industry. Anesiva Inc. has announced the publication of data from a Phase III trial of Zingo powder intradermal injection in "Journal Pediatrics." Can-Fite BioPharma has successfully completed a Phase I trial with its second pipeline drug,...

  • CLINIC ROUNDUP.  // BioWorld Today;4/2/2010, Vol. 21 Issue 63, p7 

    This section offers news briefs on clinical trials including the completion by Can-Fite BioPharma Ltd. of patient recruitment for its Phase 1/II trial of CF102 in the treatment of patients with advanced hepatocellular carcinoma and the initiation by Symphogen A/S of a Phase I/II trial in the U.S.

  • Dry-Eye Phase III Trial Enrolled, OphthaliX 'Wets' Oral Appetite. Osborne, Randy // BioWorld Today;3/19/2013, Vol. 24 Issue 52, p1 

    The article reports that OphthaliX has tackled its first-in-class A3 adenosine receptor agonist CF101 in a 24-week, 236-patient placebo-controlled Phase III trial. It states that serendipity data provided by patients in a rheumatoid arthritis (RA) trial with CF101 led to dry-eye syndrome (DES)...

  • Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achieved the Primary and secondary Endpoints.  // Biomedical Market Newsletter;1/7/2012, Vol. 21, p1 

    The article presents information on results of phase I/II clinical trials of Can-Fite BioPharma Ltd. drug candidate CF102 for the treatment of hepatocellular carcinoma (HCC). It is mentioned that the study had primarily evaluated the safety profile of long term administration of drug at three...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics